The role of COVID-19 in myopathy: incidence, causes, treatment, and prevention

J Med Life. 2022 Dec;15(12):1458-1463. doi: 10.25122/jml-2022-0167.

Abstract

Myopathy is a disease characterized by muscle dysfunction in general and may be associated with genetics, medication such as statins, or inflammation. In 2019, an epidemic viral infection (SARS-CoV-2 virus) that invaded most countries worldwide appeared and caused acute respiratory disease. Consequently, patients had to take a group of drugs for a relatively long treatment period. According to several studies, there was an increase in the cases of muscular disorders due to several factors. This study aimed to (1) investigate the relationship between COVID-19 and myopathy and (2) identify the causes and prevention methods. A systematic review was conducted, analyzing several articles from the following databases: ResearchGate, Medline, DOAJ (The Directory of Open-Access Journals), PubMed, and Google Scholar. After performing the search and filtering the results, we included 61 articles. There was a strong relationship between COVID-19 and myopathy, especially in patients admitted to the ICU department, due to medication or neurological dysregulation with multiorgan dysfunctions such as polyneuropathy, peripheral nerve involvement, dysautonomia, Guillain-Barré syndrome, and many others.

Keywords: COVID-19; SARS-CoV-2; intensive care units; muscular diseases; search engine.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • COVID-19* / complications
  • Humans
  • Incidence
  • Inflammation / complications
  • Muscular Diseases* / epidemiology
  • Muscular Diseases* / etiology
  • Muscular Diseases* / prevention & control
  • SARS-CoV-2